Zoetis Inc. (ZTS): Among The Most Oversold S&P 500 Stocks So Far in 2026

Zoetis Inc. (NYSE:ZTS) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026. On May 27, Argus Research analyst Jasper Hellweg downgraded the stock to Hold from Buy.

Zoetis Inc. (ZTS): Among The Most Oversold S&P 500 Stocks So Far in 2026

The firm noted growing competition and a shift in demand in the animal health market as the reason behind the adjustment. Argus also mentioned the risk of cannibalization with the company’s leading pipeline products likely to adversely impact the sales of its current portfolio.

The update follows Stifel’s adjustment on May 22 when it trimmed the price target on Zoetis Inc. (NYSE:ZTS) to $95 from $105 and reiterated a Hold rating. The firm believes that while the company’s revised guidance for 2026 hints at an improvement, competitive pressures “appear poised to intensify” in the short-term.

As of the close of business on May 29, Wall Street has a Moderate Buy rating on the stock with an average share price upside potential of 53%.

The company missed Wall Street’s expectations for both revenue and profit in Q1 and cut its full-year guidance, as a cautious consumer environment continues to impact demand for veterinary visits and premium pet treatments.

Zoetis Inc. (NYSE:ZTS) is a global animal health company focused on developing and commercializing vaccines and medications.

While we acknowledge the risk and potential of ZTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ZTS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Performing Defense Stocks So Far in 2026 and 10 Stocks That Will Make You Rich Over the Next Decade.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1